BOSTON ONCOLOGY ARABIA and SPIMACO Partner to Localize Advanced Oral Oncology Treatments in Saudi Arabia
In a landmark step towards advancing cancer care in the Middle East, BOSTON ONCOLOGY ARABIA and SPIMACO have signed a Memorandum of Understanding (MoU) to localize the production of advanced oral oncology treatments in the Kingdom. Announced at the CPHI Middle East conference, this partnership reflects a shared commitment to improving patient outcomes, fostering local expertise, and contributing to Saudi Arabia’s Vision 2030 goals for healthcare transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108766769/en/
In a landmark step towards advancing cancer care in the Middle East, BOSTON ONCOLOGY ARABIA and SPIMACO have signed a Memorandum of Understanding (MoU) to localize the production of advanced oral oncology treatments in the Kingdom of Saudi Arabia. (Photo: Business Wire)
Pioneering Pharmaceutical Localization
Focused on the transfer of technology and knowledge, the collaboration will enable the parties to commercialize essential oral oncology medications domestically. The initiative not only improves access to life-saving treatments, but also strengthens the Kingdom’s industrial and healthcare infrastructure.
“This agreement marks a significant milestone toward ensuring that patients in Saudi Arabia and beyond have access to world-class oncology treatments without delay,” said Dr. Abdullah Baaj, CEO of Boston Oncology Arabia. “By localizing production and investing in cutting-edge technologies, we are not just meeting immediate needs—we are modeling a sustainable future for oncology care in the GCC / MENA region.”
SPIMACO CEO Jérôme Cabannes added: "This partnership enhances our ability to provide high-quality oncology treatments and strengthens our commitment to the Kingdom's vision of a self-reliant healthcare system. It reflects our shared dedication to patient care and reinforces our leadership role in the pharmaceutical industry."
Strategic Alignment with Vision 2030
This collaboration reinforces Saudi Arabia’s leadership in regional and global pharmaceutical markets. By establishing local manufacturing capabilities for advanced oral oncology therapies, the partnership aligns with Vision 2030’s goals to reduce dependency on imports, strengthen local industry, and enhance access to innovative treatments for patients across the Kingdom.
Looking Ahead
The partnership will prioritize the commercialization of key oral oncology therapies over the next five years, driving significant benefits including job creation, the development of local expertise and production capacity, and equitable access to critical cancer treatments across Saudi Arabia and the broader MENA region.
This collaboration showcases the potential of bold strategic partnerships to unlock new opportunities to advance oncology care and address critical healthcare needs.
About Boston Oncology Arabia
Headquartered in Riyadh, Boston Oncology Arabia is a leading pharmaceutical company with a mission to impact the lives of one billion patients by 2030. The company is recognized for its innovative approach to conquering market complexity, delivering the full value of its products to the market while achieving outsized and sustainable competitive share. Focused on the licensing, local development, and manufacturing of world-class medicines, Boston Oncology Arabia’s end-to-end supply chain ensures transformative access to essential therapeutics—reaching hospital systems swiftly, reliably and affordably.
Learn more at https://bostononcology.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108766769/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy9.1.2025 09:00:00 CET | Press release
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for thetreatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway). This approval of the extension of indication of Palforzia® to toddlers, follows the July 2024 approval by the U.S. Food and Drug Administration (FDA). Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy. “Peanut allergy is one of the most frequent food allergies. Early intervention is crucial to reduce the risks of accidental exposure and may be very important in improving long-term outcomes. The approval of Palforzia for toddl
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference9.1.2025 08:37:00 CET | Press release
Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann Pick type C (NPC). Positive topline data reported earlier this year from the company’s successful Phase 2 study investigating nizubaglustat in GM2 and NPC patients demonstrated that the compound had a positive safety profile. Preliminary improvements or stabilization of clinical endpoints were observed in the majority of patients, highlighting encouraging early efficacy trends for the compound. Azafaros is preparing to initiate Phase 3 studies with nizubaglustat in
Kaneka Acquires EndoStream Medical Ltd.9.1.2025 06:21:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) acquired 96.8% of shares of EndoStream Medical Ltd. (Headquarters: Or Akiva, Israel; CEO: Danel Mayer; hereinafter referred to as ESM), an Israeli medical equipment company, on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus™ device for aneurysm treatment currently under development. We aim to achieve sales of over 20 billion yen by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108226003/en/ Cerebral aneurysm treatment device “Nautilus™” (Graphic: Business Wire) ESM is a manufacturer of innovative technologies in the field of cerebrovascular diseases and is developing a device for the treatment of cerebral aneurysms called “Nautilus™” that can treat aneurysms with wide openings in cerebr
KRAFTON Showcases AI Model ‘CPC’ Built with NVIDIA ACE at CES 20259.1.2025 03:37:00 CET | Press release
Shaping the future of gaming with KRAFTON’s AI technology and NVIDIAHands-on demo features CPC technology applied to the PUBG IP Franchise and inZOI KRAFTON (CEO Changhan ‘CH’ Kim) set a new milestone for the global gaming industry with the introduction of ‘CPC’ (Co-Playable Character), an NPC (Non-Player Character) brought to life with generative AI, in collaboration with NVIDIA, at the world’s largest IT exhibition CES 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108628507/en/ Kangwook Lee, Head of the Deep Learning Division at KRAFTON (Photo: KRAFTON) On January 8, KRAFTON joined NVIDIA at the Fontainebleau Hotel in Las Vegas. KRAFTON showcased an innovative AI experience built with NVIDIA ACE technologies, presenting a bold vision for the future of gaming. Kangwook Lee, Head of the Deep Learning Division at KRAFTON, demonstrated CPC, describing it as “a groundbreaking character concept enabled by an on-device
LR Health & Beauty Celebrates Its 40th Anniversary8.1.2025 15:04:00 CET | Press release
Social Commerce Company has been giving sales partners and customers a better quality of life with high-quality product solutions for four decades The Social Commerce Company LR Health & Beauty is looking back on 40 years of company history this year. The company, which was founded in 1985, has developed into a global player in the direct selling industry in recent years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108836518/en/ LR Headquarters (Photo: Business Wire) LR Health & Beauty has been setting innovative trends in the nutritional supplements and cosmetics sector for 40 years. The unique selling point: The products are sold by independent sales partners who earn an additional income by recommending products and setting up their own business. "LR stands for quality, innovation and a strong people business that offers an attractive business model to people who want more flexibility, more self-fulfilment and finan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom